Cue Biopharma (NASDAQ:CUE) stockholders approved three proposals at a virtual special meeting, including authorization for the issuance of common stock tied to certain warrants issued in May 2026 in connection with a licensing transaction and related private placement.
The meeting was called to order by Shao-Lee Lin, Cue Biopharma’s President and Chief Executive Officer, who served as presiding officer. Tony Carideo of the Carideo Group acted as Inspector of Election, and Colin Sandercock, the company’s Senior Vice President, General Counsel and Secretary, served as secretary of the meeting.
Quorum Established for Special Meeting
The company set May 8, 2026, as the record date for the special meeting. Lin said an affidavit certified that notice of the meeting had been provided to stockholders of record as of that date.
Carideo reported that a preliminary count showed holders of a majority of Cue Biopharma’s common stock issued and outstanding as of the record date and entitled to vote were represented at the meeting, either virtually or by proxy. Based on that report, Lin declared that a quorum was present and that the meeting was ready to conduct business.
Stockholders Vote on Three Proposals
The company presented three items for stockholder consideration:
- Approval, under Nasdaq Listing Rules 5635(a), (c) and (d), of the issuance of shares of common stock upon the exercise of certain warrants issued by the company in May 2026 in connection with a licensing transaction and related private placement.
- Approval of the Cue Biopharma, Incorporated 2026 Stock Incentive Plan.
- Approval to adjourn the special meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies if there were insufficient votes or otherwise in connection with the first two proposals.
Lin said stockholders could vote through the virtual meeting portal until the polls were closed. She also said shares represented by proxy would be voted as specified, and shares represented by proxy without a specified vote would be voted in line with the recommendation of Cue Biopharma’s board of directors.
Preliminary Results Show All Proposals Approved
After the polls closed, Lin said Cue Biopharma had been informed by the Inspector of Election that, based on preliminary results, stockholders approved all three proposals.
The approvals included the Nasdaq-related proposal covering the issuance of common stock upon the exercise of certain warrants issued in May 2026 as part of the licensing transaction and related private placement. Stockholders also approved the company’s 2026 Stock Incentive Plan and the potential adjournment proposal.
Lin said the company expects to report preliminary voting results, or final voting results if available on a timely basis, in a current report on Form 8-K to be filed with the SEC within four business days after the meeting. If final results are not available at that time, the company expects to report them in an amendment to the Form 8-K within four business days after the final results are known.
The meeting was then adjourned.
About Cue Biopharma (NASDAQ:CUE)
Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.
